

Utilization of Lipopeptides or Lipoproteins in Wound Treatment and Infection Prophylaxis

RECEIVED

AUG 20 2002

State of the art

5

Five stages of wound healing can be described:

OFFICE OF PETITIONS

10

1. Coagulation of blood and release of mediators from thrombocytes (after a few minutes),
2. inflow of leukocytes, that is, initially granulocytes, later macrophages and lymphocytes (day 1-3),
3. multiplication of various cells, such as fibroblasts, endothelial and epithelial cells (day 3-7),
4. wound contraction (day 7-9), and
5. rebuilding of the scar tissue (up to one year).

15

The inflow of granulocytes in Phase 2 causes the uptake of debris and killing of infectious germs, a task which is also taken over by macrophages.

20

Moreover, macrophages are the source of a number of mediators, such as signal peptides, growth factors and cytokines, such as the Transforming Growth Factor (TGF β 1), Platelet-Derived Growth Factor (PDGF-AA and BB), Fibroblast Growth Factor (FGF2) and TGF- α , which belongs to the family of the Epidermal Growth Factor (EGF). Macrophages also secrete interleukin-1 (IL-1), which induces FGF7 in the fibroblasts indirectly. All these factors participate in the different stages of wound healing and are indispensable for it. Without macrophages as a source for these, wound healing is highly delayed or is not possible.

25

Problems

30

Although it is possible to use some of the mediators mentioned above in the isolated form during wound healing, this is ineffective since most of these peptides have a half-life of only a few minutes. Other difficulties consist in the fact that the natural point in time of the appearance of the different mediators, the optimal dosage and the interaction of these substances are not known in detail, and therefore could not be controlled during application.

A complication of surgical wounds, too, can be infections which generally lead to delay in wound healing and to an increase of the formation of scar

tissue, which is problematic, especially in the case of cosmetic operations. Prophylactic coverage with antibiotics is not used any longer in many places, considering resistance problems and possible allergic reactions. In certain patient groups, for example, in diabetics or in elderly patients, wound healing is delayed.

5


Solution

Mycoplasmas naturally have the property of inducing the inflow of leukocytes at the location of infection, for example, in the lung. As we were able to show, this property is associated with the presence of a certain class of lipopeptides, which is characterized by the fact that they have an N-terminal with a dihydroxypropyl cysteine group to which two long-chain fatty acids are bonded via ester bonds [Mühlradt *et al.*, *J. Exp. Med.*, **185**:1951-1958, (1997) and Mühlradt *et al.*, *Infect. Immun.*, **66**:4804 (1998)]. In addition to the property already described, to stimulate murine as well as human macrophages and monocytes *in vitro* to liberate cytokines and prostaglandins (1 to 3; 11), these lipopeptides also have the ability, newly discovered by us, to induce *in vivo* a high titer of the chemokines MIP-1 α , MIP-2, MCP-1 and KC and to cause the migration of leukocytes into the area [Deiters & Mühlradt, *Infect. Immun.*, **67**:3390 (1999)]. These lipopeptides stimulate the cells via the "toll-like receptor 2" [Takeuchi *et al.*, *J. Immunol.*, **164**:554 (2000)].

In animal as well as human medicine, pure, synthetically produced lipopeptides, as well as lipopeptides that are encapsulated into liposomes or are coupled to biodegradable polymeric carriers can be used, for example, in the form of salves, lotions or injection solutions. When applied to wounds or injected near the wound, such preparations are supposed to increase and accelerate the natural inflow of granulocytes and macrophages and thus prevent infection as well as facilitate and accelerate wound healing by stimulation of the biosynthesis of mediators participating in wound healing, in the natural sequence and concentration. The *in vivo* effectiveness of such lipopeptides from mycoplasmas is surprising and new, since the application of other bacterial lipopeptides and their synthetic analogs do not show any effect in animal experiments [Hauschild *et al.*, *FEMS Immunol. Med. Microbiol.*, **8**:77 (1994)].

30

According to an embodiment, the problem underlying the invention is solved by the use of a lipopeptide or lipoprotein with the following general structure:



in which

10 R^1 and R^2 , which can be the same or different, stand for C_{7-25} -alkyl, C_{7-25} -alkenyl or C_{7-25} -alkinyl,

X is S, O or CH_2 ,

Z^1 and Z^2 , which can be the same or different, stand for H or methyl,

W stands for CO or $\text{S}(\text{O})_n$ (where $n = 1$ or 2) and

15 Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues, and the asymmetric carbon atom marked with * has the absolute S-configuration when $\text{X} = \text{S}$ (sulfur),

for the preparation of a pharmaceutical preparation for animal or human wound treatment.

20 According to the invention, the lipopeptide or lipoprotein can be characterized by the fact that Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acids.

According to the invention, the lipopeptide or lipoprotein can be characterized by the fact that Y stands for an amino acid sequence which is selected from the following group:

- 25
- (i) amino acid sequence, which does not have an adverse influence on the water solubility of the lipopeptide or lipoprotein.
 - (ii) GQTNT

- (iii) SKKKK
- (iv) GNNDESNISFKEK
- (v) GQTDNNSSQSQQPGSGTTNT

5 in the case of amino acid sequences (ii), (iii), (iv) and (v), individual amino acids may be absent or replaced.

According to the invention, the C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl or C₇₋₂₅-alkinyl can be a C₁₅-alkyl, C₁₅-alkenyl or C₁₅-alkinyl.

10 According to the invention, in the C₇₋₂₅-alkenyl group, the double bond(s) have the cis-configuration.

According to another embodiment, the task on which the invention is based, to prepare a pharmaceutical preparation for the treatment of animal and human wounds, is solved by the use of a physiologically compatible lipopeptide or lipoprotein, in which the N-terminal carries a dihydroxypropyl cysteine group with
15 two optionally long-chain fatty acids, which can be the same or different, bonded via ester bonds.

Furthermore, the invention concerns the use of a lipopeptide or lipoprotein, obtainable from a mycoplasma clone, for the preparation of a pharmaceutical preparation for animal or human wound treatment.

20 This application can be characterized by the fact that the lipopeptide or lipoprotein is obtainable from a Mycoplasma fermentans clone.

In the application according to the invention, the lipopeptide or lipoprotein can be water-soluble or amphoteric.

25 According to the invention, a lipopeptide or lipoprotein from the following group can be used:

- (i) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GQTNT
- (ii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-SKKKK
- (iii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GNNDESNISFKEK
- 30 (iv) S-[2,3-bispalmitoyloxy-(2S)-propyl]cysteinyl-GNNDESNISFKEK

(v) S-[2,3-bispalmitoyloxypropyl]cysteinyl-
GQTDNNSSQSQQPGSGTTNT.

In the application according to the invention, the lipopeptide or
5 lipoprotein can be used in the form of a solution for epicutaneous application, as an
injection solution, as salve, as lotion, as aqueous suspension, a patch impregnated or
coated with it, encapsulated in liposomes or coupled to biodegradable carrier
polymers.

In the application according to the invention, the wounds can be
10 wounds after injuries or surgical intervention, in order to treat chronically infected
wounds, burn wounds, chronic ulcers or Ulcus venosum or wounds of patients who
are corpulent or diabetic or were subjected to radiation or chemotherapy.

Synthetic lipopeptide preparations could be manufactured
inexpensively and would enhance the natural progress of wound healing without
15 causing any alteration in principle in the complicated regulatory mechanism of
various mediators in wound healing. Moreover, infection prophylaxis would be
achieved without having to use of antibiotics or other bacteriostatics that, for example,
would affect wound healing. Such lipopeptide preparations could also be used for
wounds on the face, where, for reasons of toxicity, the usual bacteriostatics are
20 forbidden, when there is a danger of contact with the eyes or the nasal and oral
regions. In topical applications, the danger of systemic effects, such as fever, is
practically completely excluded.

The invention will be explained below in more detail with the aid of
figures and examples.

25 **Example 1**

Macrophage activation by synthetic lipopeptides derived from
mycoplasmas, measured with the nitrogen monoxide liberation assay

An easily quantifiable assay for the activation of murine macrophages
with lipopeptides is the liberation of nitrogen monoxide from peritoneal exudate cells
30 in the presence of interferon- γ ; see, for example, Mühlradt & Frisch, *Infect. Immun.*,
62:3801-3807 (1994). This assay is carried out with peritoneal exudate cells of
C3H/HeJ mice, which react only slightly with endotoxin, using microtiter plates (96

wells). Simultaneously, 10^5 cells are stimulated with recombinant IFN- γ and a serial dilution of a material which activates macrophages. After incubation for 48 hours, the nitrate is reduced with nitrate reductase; NO is determined as the sum of nitrite and nitrate with the Griess reagent.

5 The macrophage-stimulation activity of the following lipopeptides is compared in Figures 1A to 1D.

Figure 1A: MALP-A:S-[2,3-Bisphosphatidoyloxy-(2RS)-propyl]cysteinyl-SKKKK.

10 Figure 1B: N-Palmitoyloxy-MALP-A:S-[2,3-Bisphosphatidoyloxy-(2RS)-propyl]-N-palmitoyl-cysteinyl-SKKKK.

Figure 1C: MALP-H: S-[2,3-Bisphosphatidoyloxy-(2RS)-propyl]-cysteinyl-GQTNT.

15 Figure 1D: S-MALP-2: S-[2,3-Bisphosphatidoyloxy-(2S)-propyl]-cysteinyl-GNNDESNISFKEK; and R-MALP-2: S-[2,3-Bisphosphatidoyloxy-(2R)-propyl]cysteinyl-GNNDESNISFKEK.

20 With the aid of this assay, it is shown that the length or composition of the peptide portion of the lipopeptide has little influence on the macrophage-stimulation activity (see Figures 1A, 1C and 1D), while the number of fatty acids at the N-terminus (see Figures 1A and 1B) and especially the steric configuration in the 2-position of the diacyloxypropyl group is of influence (see Figure 1D).

Example 2

The model of inflow of granulocytes and macrophages into the peritoneal cavity of the mouse served as an example of the effectiveness of synthetic lipopeptides or liposomes into which such lipopeptides were incorporated. NMRI-outbred mice were used as experimental animals in order to exclude genetic peculiarities.

The racemic lipopeptide MALP-2 was synthesized according to Mührladt *et al.*, *J. Exp. Med.*, **185**:1951-1958 (1997)], the compounds R-MALP-2 = S-[2,3-Bisphosphatidyl-(2R)-propyl]cysteinyl-GNNDESNISFKEK or S-MALP-2 = S-[2,3-Bisphosphatidyl-(2S)-propyl]cysteinyl-GNNDESNISFKEK were synthesized according to reference [Metzger *et al.*, *J. Medicinal Chem.*, **34**:1969-1974 (1991)]. MALP-containing liposomes were constructed as follows: The lipids dissolved in chloroform or chloroform/methanol (1 + 1) (phosphatidyl glycerol, phosphatidyl serine, cholesterol, NBD-PE, molar ratio 1.08 : 1 : 0.25 : 0.005) were pipetted together with the MALP-2 dissolved in 2-propanol/H₂O (1 + 1) and evaporated using a rotary evaporator. Complete drying of the lipid film occurs overnight in a sterile work bench. Dissolution of the dry lipid film in octyl glucoside (100 mM in 0.05 M Tris-buffered NaCl, pH 7), for 30 minutes at 37°C in a water bath. Dialysis against a 50-fold volume of NaCl (buffered with 0.1 M Tris, pH 7) at room temperature, replacement of the outside dialysate twice, each time after 24 hours.

The obtained liposome suspension is washed 3x with NaCl (centrifuging for 30 minutes at 47,800 g, 4°C) and then resuspended in NaCl.

At time 0, the following preparations are injected in a sterile manner and in physiological sodium chloride solution into the peritoneal cavity of the experimental animals. Groups of 6 mice were killed after different times, the peritoneal cavity was washed with 1.2 ml of sterile sodium chloride solution and the number of leukocytes and the leukocyte composition was determined in this cell suspension.

Figure 2 shows the inflow of the total leukocytes and granulocytes as a reaction to the intraperitoneal injection of 9 µg of racemic MALP-2 into NMRI mice (groups of 6 animals).

Figure 3 shows the inflow of the total leukocytes and granulocytes as a reaction to the intraperitoneal injection of 0.2 mg of liposomes, which contained 9 µg of racemic MALP-2, in NMRI mice (groups of 6 animals).

5 Figure 4 shows the inflow of total leukocytes and granulocytes as a reaction to the intraperitoneal injection of 0.2 mg of control liposomes which contained no MALP-2, in NMRI mice (groups of 6 animals).

Figure 5A shows the infiltration of leukocytes in the skin on the back of an NMRI mouse, 3 days after intracutaneous injection of 2 µg of S-MALP-2, which was incorporated into liposomes.

10 Figure 5B shows, in comparison: the skin on the back of an untreated mouse.

Figure 6 shows the area of new tissue with new vessels (middle of the picture) formed after MALP injection.

15 Table 1 shows the essential values, that is, the increase of granulocytes after the injection of the preparations and the later increase of macrophages. In comparison to untreated control animals, an increase of the granulocytes by about 100 times is found, while the macrophages increased two to three times after 3 days.

20 Significantly increased activities are found in the chemotactically effective chemokines MIP-1α, MIP-2 or KC in the serum of experimental animals measured 2 hours after application of the mycoplasmas or lipopeptide preparations.

Example 3:

25 The importance of the asymmetric C-atom at C2 of the dihydroxypropyl group for the *in vivo* effect is shown in Table 2. Here, as above, groups of 5 NMRI mice were treated with different amounts of R-MALP-2 = S-[2,3-Bispalmitoyloxy-(2R)-propyl]cysteinyl-GNNDESNISFKEK or S-MALP-2 = S-[2,3-Bispalmitoyloxy-(2S)-propyl]cysteinyl-GNNDESNISFKEK applied intraperitoneally, and after 3 days the total number as well as the composition of the peritoneal leukocytes were determined. S-MALP-2 is clearly more effective.

Example 4:

The following experiment was carried out in order to show the effect of MALP-2 upon intracutaneous application. When 2 µg of free S-MALP or 2 µg of S-MALP incorporated in 0.1 mg of liposomes is applied intracutaneously in the skin of NMRI mice, a clear accumulation of leukocytes is observed at the injection site after 3 days (see Figures 5A and 5B) and, after 6 days, new tissue and vessels are formed (Figure 6). This shows that the preparations are effective in the skin and are able to promote wound healing.

Example 5:

Effects of topical application of S-MALP-2 on the infiltration of cells and wound healing in mice.

In order to establish a dose response, two types of experiments were carried out:

1. Determination of infiltration of cells and proliferation by measurement of nucleic acids in skin sections after intracutaneous (ic) injection of various MALP-2 doses. On day 1, the back of C57BLKS/J mice was shaved and hair was removed with Veet. On day 0, the animals were anesthetized with metofane; various doses of MALP-2, dissolved in 30 percent 2-propanol, were injected in volumes of up to 10 µL onto the back (ic). Corresponding volumes of the vehicle without MALP-2 were injected onto the back of the same mice at another location. The animals were killed 10 days later, and punched skin sections (diameter 0.8 cm) were taken from the MALP-2 injection sites and from the control injection sites. The skin biopsies were defatted by extraction with methanol, methanol/chloroform (1 + 1) and chloroform for 15 minutes and were hydrolyzed in 10 N HCl overnight at 110°C. The samples were dried, taken up in water and clarified by filtration through a sterile filter (0.2 µm); the nucleic acids were determined by measuring the absorption at 260 nm. Thus, 5 µg of MALP-2 per injection site was found to be optimal. At this dose, the nucleic acid content increased at the MALP-2 injection site by $97 \pm 43\%$ in comparison to the corresponding control biopsy (4 animals per group).

2. Cell colonization and proliferation were measured in the skin section (0.8 cm diameter) of wounds which were treated with various amounts of MALP-2. For this experiment, (C57BLKS/J-m+/+Lepr^{db} mice (diabetic) were

shaved on the back and hair was removed with Veet. The animals were anesthetized with metofane and their backs were disinfected with Braunol. Then circular skin segments (0.8 cm diameter) were taken from the back of each mouse. The wounds were covered with transparent hydrofilm (Hartmann, Germany); MALP-2 or other
5 vehicles were injected into the wound bed through the film in a volume of 50 μ L. After 10 days, the animals were killed; the thin layer of cells, which closes the wound, was sectioned (0.8 mm diameter). The punched samples were hydrolyzed and the nucleic acids determined as before. In this model, too, a dose of 5 μ g of MALP-2 per wound was found to be optimal. At this dose, 349 ± 24 μ g of nucleic acid per biopsy
10 sample were found in the animals treated with MALP-2 while the value was 142 ± 22 μ g in the comparison samples (4 animals per group; $p < 0.0001$).

A wound-healing experiment was carried out as follows. On day 1, (diabetic) C57BLKS/J-m+/+-Lepr^{db} mice were shaved on the back. On day 0, the animals were anesthetized with ether and the backs were disinfected with
15 Braunoderm. After that, circular regions (1.3 cm diameter) were cut from the skin of the back of each mouse. The edges of the wound were treated with benzoin tincture; then 100 μ L of the MALP-2 preparation or of the vehicles were introduced into each wound (10 mice for each treatment group). The wounds were covered with transparent patches of Tegaderm. Each day, up to day 4, 100 μ L of the preparation
20 (content 5 μ g of MALP-2) or vehicle preparation was injected into the wound bed through the Tegaderm patches or placed in the wound when the bandage was changed. The mice were kept individually in separate cages. In order to avoid infections, baytril (Bayer) was introduced in the drinking water (50 mg/L of enrofloxacin). The bandages were changed once a week under ether anesthesia, and
25 the wound edges were recorded on microscope slides. The areas shown were determined with a standard CCD camera using ScionImage software. The wounds were checked visually for infections; liquid samples from obviously infected wounds were tested on blood agar plates. Mice with infected wounds were removed from further analyses. The data are given in Figure 7 and show a significant acceleration of
30 wound healing in the case of the animals treated with S-MALP-2.

Example 6: Increase of the survival rate of mice in a peritonitis model by pretreatment with MALP-2

"Colon ascendens stent peritonitis" is a new model for abdominal sepsis, which may follow surgical intervention [Zantl *et al.*, *Infekt. Immun.*, **66**:2300-2309 (1998)]. The following experiments were carried out in order to evaluate the ability of MALP-2 to increase the survival rate in this model. Groups of 12 to 18 C57BL/6 mice were injected intraperitoneally with 2 µg of S-MALP-2 in 200 µL of physiological sodium chloride solution or with the same volume of physiological sodium chloride solution either 2 or 4 days before surgical intervention. The surgical intervention was carried out under ether anesthesia. The abdomen was disinfected with 70% ethanol and then opened by section in the middle line (1 cm). A venous catheter (16 gauge) was inserted into the lumen of the descending colon and secured with two stitches using Ethilon thread (7/0). Then the inner needle of the stent was removed, the catheter was shortened to a length of a few millimeters and a small drop of feces was pressed out from the catheter. The peritoneal cavity was rinsed with 0.5 MI of sodium chloride solution before closing the abdomen. Among the mice with the control, sodium chloride solution (18 per group), none lived longer than 90 h. Among those who were treated two days before the surgical intervention with MALP-2, 4 out of 12 survived for 150 h or longer, while among the animals who were treated with MALP-2 four days before the surgical intervention, 6 animals out of 12 survived for 120 hours and longer. The difference of survival rate was statistically significant ($P < 0.001$ according to the log-rank test).

Referenced state of the art

- [1] Quentmeier et al. in *Infect. Immun.*, 58 (1990) 1273-1280
- [2] Mührladt & Frisch in *Infect. Immun.*, 62 (1994) 3801-3807
- 5 [3] Mührladt & Schade in *Infect. Immun.*, 59 (1991) 3969-3974
- [4] Metzger et al. in *Int. J. Pep. Protein Res.*, 38 (1991) 545-554
- [5] Metzger et al. in *J. Pept. Sci.*, 3 (1995) 184-190
- [6] Mührladt et al. in *J. Exp. Med.*, 185 (1997) 1951-1958
- [7] Metzger et al. in *J. Medicinal Chem.*, 34 (1991) 1969-1974
- 10 [8] Hausschild et al. in *FEMS Immunol. Med. Microbiol.*, 8 (1994) 77
- [9] Zantl et al. in *Infekt. Immun.*, 66 (1998) 2300-2309
- [10] Mührladt et al. in *Infect. Immun.*, 66 (1998) 4804
- [11] Kaufmann et al., in *Infect. Immun.*, 67 (1999) 6303
- [12] Deiters & Mührladt in *Infect. Immun.*, 67 (1999) 3390
- 15 [13] Takeuchi et al. in *J. Immunol.*, 164 (2000) 554

Table 1. Leukocyte inflow as a sequel to intraperitoneal injection of racemic MALP-2 after 72 hours

Treatment	Peritoneal cells	Monocytes + macrophages		Lymphocytes		Granulocytes	
	(x 10 ⁶)	(x 10 ⁶)	(%)	(x 10 ⁶)	(%)	(x 10 ⁶)	(%)
MALP-2 (9 µg)	11.2 ± 3.1 ^b	5 ± 1.2 ^b	47.4 ± 15.2	3.5 ± 1.2	32 ± 11 ^b	2.6 ± 2.7	20.2 ± 13.2 ^b
liposome-encapsulated MALP-2 (9 µg)	8.5 ± 1.2 ^c	4.9 ± 0.9 ^c	57.6 ± 8.1 ^c	2.9 ± 1	33.4 ± 9 ^c	0.8 ± 0.2 ^c	9.7 ± 2.2 ^c
control liposomes	6.4 ± 1.9	2.9 ± 1.2	44.5 ± 6.8	3.2 ± 0.9	51.8 ± 6.7	0.2 ± 0.08	2.9 ± 1.4
NaCl (0.9%)	5.8 ± 0.5	2.8 ± 0.4	47.9 ± 1.7	2.8 ± 0.2	48.8 ± 1	0.05 ± 0.03	0.9 ± 0.6

5

Groups of 6 animals were used.

^b Significant difference (P < 0.05) in comparison to control animals treated with sodium chloride (according to the Student t-test).

10

^c Significant difference (P < 0.05) in comparison to the animals which received the control liposomes (according to the Student t-test).


Table 2: Leukocyte inflow 72 hours after intraperitoneal injection of R-MALP-2 or S-MALP-2

		PEC	macrophages		lymphocytes		neutrophils	
		(x 10 ⁶)	(x 10 ⁶)	%	(x 10 ⁶)	%	(x 10 ⁶)	%
control	A	5.4	2.9	54	2.2	40.7	0	0
	B	6.4	3.8	58.6	2.4	38.1	0.19	0.3
	C	7.95	4.1	52.6	3.4	43.1	0.24	0.3
	D	7.5	2.9	38.5	4.4	57.9	0	0
	E	5.1	2.7	53.4	2.2	44	0	0
	φ	6.5 ± 1.3	3.3 ± 0.6	51.4 ± 7.6	2.9 ± 0.9	44.8 ± 7.7	0.09 ± 0.1	0.12 ± 0.16
R-MALP (10 µg)	A	11.1	4.5	40.1	6.3	56.5	0.56	0.5
	B	4.05	2.1	52.4	1.8	45.2	0.32	0.8
	C	11.4	6	53	5	44.2	0.34	0.3
	D	7.65	4	52.6	3.4	44.4	0	0
	E	9	4.6	51.3	4.1	45.6	0.27	0.3
	φ	8.64 ± 3	4.2 ± 1.4	49.9 ± 5.5	4.1 ± 1.7	47.2 ± 5.2	0.3 ± 0.2	0.4 ± 0.3
S-MALP (1 µg)	A	9.1	4.5	49.9	4.2	46.3	0.46	0.5
	B	10.8	4.7	43.8	5.2	48.3	3	2.8
	C	9.35	5.3	56.9	2.6	27.8	12	12.8
	D	13.7	8.4	61.6	4	29.4	10.1	7.4
	E	7.9	4.6	58.5	2.8	34.9	2.8	3.5
	φ	10.2 ± 2.2 ^a	5.5 ± 1.7 ^a	54.1 ± 7.2	3.8 ± 1.1	37.3 ± 9.5	14.8 ± 17.9 ^{a, b}	5.4 ± 4.8 ^{a, b}
S-MALP (5 µg)	A	14.4	6.3	44.1	5.1	35.2	25.9	18
	B	15.2	5.6	37.2	5.4	35.5	41	27
	C	17.3	6.1	34.8	10	58.1	8.1	4.7
	D	13.1	5.4	41.5	2.8	21.5	45.5	34.7
	E	12.5	6.3	50.7	4.2	33.4	17.3	13.8
	φ	14.5 ± 1.9 ^{a, b}	5.9 ± 0.4 ^{a, b}	41.7 ± 6.2	5.5 ± 2.7	36.7 ± 13.3	27.6 ± 15.7 ^{a, b}	19.6 ± 11.6 ^{a, b}

- ^a Significant differences in comparison to the control animals (no injection).
- ^b Significant differences to the animals treated with R-MALP (10 µg).

Patent Claims 1 to 12

1. Application of a lipopeptide or lipoprotein with the following
5 general structure:



10 in which

R^1 and R^2 , which can be the same or different, stand for C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl or C₇₋₂₅-alkinyl,

X is S, O or CH₂,

Z^1 and Z^2 , which can be the same or different, stand for H or methyl,

15 W stands for CO or S(O)_n (where n = 1 or 2) and

Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues and the asymmetric carbon atom marked with * has the absolute configuration S when X = S (sulfur), for the preparation of a pharmaceutical preparation for treatment of wounds in animals or humans.

20 2. Application according to Claim 1, characterized by the fact that Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acids.

3. Application according to Claim 1, characterized by the fact that Y stands for an amino acid sequence which is selected from the following group:

- 25 (i) amino acid sequence, which does not have an adverse influence on the water solubility of the lipopeptide or lipoprotein.
- (ii) GQTNT

- (iii) SKKKK
- (iv) GNNDESNISFKEK
- (v) GQTDNNSQSQQPGSGTTNT

5 where, in amino acid sequences (ii), (iii), (iv) and (v), individual amino acids may be absent or replaced.

4. Application according to one of the previous Claims, where the C₇₋₂₅-alkyl, C₇₋₂₅-alkenyl or C₇₋₂₅-alkinyl is a C₁₅-alkyl, C₁₅-alkenyl or C₁₅-alkinyl.

10 5. Application according to one of the previous Claims, where the double bond(s) in the C₇₋₂₅-alkenyl group has(have) the cis-configuration.

6. Application of a physiologically compatible lipopeptide or lipoprotein which carries at the N-terminal a dihydroxypropyl cysteine group with two, optionally long-chain, fatty acids bonded via ester bonds, which can be the same or different, for the preparation of a pharmaceutical preparation for the treatment of
15 animal and human wounds.

7. Application of a lipopeptide or lipoprotein obtainable from a mycoplasma clone for the treatment of wounds in animals or humans.

8. Application according to Claim 7, characterized by the fact that the lipopeptide or lipoprotein can be obtained from a Mycoplasma fermentans clone.

20 9. Application according to one of the previous Claims, where the lipopeptide or lipoprotein is water-soluble or amphoteric.

10. Application according to one of the previous Claims of a lipopeptide or lipoprotein selected from the group

- (i) S-[2,3-bisphosphatidyl-oxy-(2RS)-propyl]cysteinyl-GQTNT
- 25 (ii) S-[2,3-bisphosphatidyl-oxy-(2RS)-propyl]cysteinyl-SKKKK
- (iii) S-[2,3-bisphosphatidyl-oxy-(2RS)-propyl]cysteinyl-
GNNDESNISFKEK
- (iv) S-[2,3-bisphosphatidyl-oxy-(2S)-propyl]cysteinyl-
GNNDESNISFKEK

(v) S-[2,3-bispalmitoyloxypropyl]cysteinyl-
GQTDNNSSQSQQPGSGTTNT

11. Application according to one of the previous Claims, where the
lipopeptide or lipoprotein can be in the form of a solution for epicutaneous
5 application, an injection solution, a salve, a lotion, an aqueous suspension, a patch
impregnated or coated with it, encapsulated in liposomes or coupled to biodegradable
carrier polymers.

12. Application according to one of the previous Claims, with the
wounds being wounds after injury or surgical intervention, chronically infected
10 wounds, burn wounds, chronic ulcers or Ulcus venosum or wounds of patients who
are corpulent or diabetic or are subjected to radiation or chemotherapy.

Summary

- The invention concerns a pharmaceutical preparation for the treatment of wounds in animals or humans containing or consisting of a lipopeptide or
- 5 lipoprotein which carries at the N-terminals a dihydroxypropyl-cysteine group with two, optionally long-chain, fatty acids bonded via ester bonds.